Anthropic

President Trump has pushed to accelerate artificial intelligence development with minimal regulation, but Anthropic has become an obstacle to that agenda. The company's safety-focused stance and disagreements with the White House over how fast and freely AI should advance have put it at odds with an administration otherwise eager to champion the industry.

A U.S. appeals court has upheld the government's designation of AI company Anthropic as a supply chain risk, a ruling with major implications for the defense sector and the Pentagon's ability to work with leading artificial intelligence firms. The decision resolves a legal challenge to the classification, which can restrict or complicate federal contracts involving the company's technology.

A new antitrust lawsuit targets Anthropic, OpenAI, xAI and Google, alleging the AI companies agreed among themselves to slow the pace of AI development. Plaintiffs argue the alleged plan had been in motion for months before the companies publicly described any such agreement as self-serving. If the claims hold up, the case could become a major test of how competition law applies to coordination among leading AI labs.

A new episode of the All-In Podcast covers mounting speculation that Anthropic's planned IPO could be at risk, alongside discussion of Meta's Muse gaining popularity, falling token prices, open source models gaining market share, and renewed concerns about AI alignment failures. The panel weighs what these shifts mean for the competitive balance among leading AI companies.

Anthropic has agreed a $12 billion deal with Akamai for AI computing capacity, according to a Bloomberg report. The agreement adds another major infrastructure supplier to the AI company's computing arrangements and underlines the enormous sums being spent on compute as firms race to build and serve large AI models. Details on timelines and how the capacity will be used were not disclosed.

Anthropic says its Claude AI model has independently discovered a new enzyme system after analysing DNA databases, marking the first discovery to come out of the company's newly established biotech laboratory. The announcement is being shared widely in German-language tech and science circles, with commentators framing it as a milestone for AI-assisted biological research.

Anthropic says its Claude AI helped identify a previously unknown gene-editing enzyme, a claim that, if verified, would mark a significant moment for AI-driven scientific discovery. However, the finding has not yet been independently confirmed by the scientific community, and experts are urging caution until the results are peer-reviewed or replicated in the lab.

OpenAI and Anthropic have found that AI safety incidents occur at a scale well beyond what either company has previously disclosed publicly, according to a report picked up by technology news outlets. The finding suggests internal monitoring of model failures and misuse reveals more problems than companies currently share with the public.